Differences in the spectrum of steroidogenic enzyme inhibition between Osilodrostat and Metyrapone in ACTH-Dependent Cushing Syndrome Patients.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of endocrinology"
DOI: 10.1530/eje-22-0208
Abstract: INTRODUCTION Osilodrostat is a new 11 ß-hydroxylase inhibitor with a mode of action analogue to Metyrapone. The objective of this study was to compare steroidogenic profiles in patients treated by either Osilodrostat or Metyrapone for… read more here.
Keywords: endocrinology; patients treated; osilodrostat metyrapone; acth dependent ... See more keywords